{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:23:41Z","timestamp":1782102221058,"version":"3.54.5"},"reference-count":24,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>The maximum dose of IGF-I recommended for treatment of GH insensitivity is commonly used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>The aim was to test the hypothesis that a lower dose is as effective as a high dose of IGF-I in growth promotion and has fewer deleterious effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and Setting:<\/jats:title>\n                  <jats:p>Subjects were treated for 3 years with regular examinations including bone age and dual energy x-ray absorptiometry and for 1 year with abdominal ultrasound studies at a clinical research institute in Quito, Ecuador.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Subjects:<\/jats:title>\n                  <jats:p>The study included 21 subjects ages 3.2\u201315.9 years with GH insensitivity due to the same splice site mutation on the GH receptor gene.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions:<\/jats:title>\n                  <jats:p>Subjects were allocated to receive 120 (n = 14) or 80 (n = 7) \u03bcg\/kg IGF-I twice daily.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures:<\/jats:title>\n                  <jats:p>Height velocity, osseous maturation, height SD scores (SDS), body composition, abdominal organ growth, and side effects were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>There were no differences in growth velocity or height SDS increment by dosage, and the SDS increase was greater than in other reported series. Osseous maturation over 3 years with the high dose was nearly twice as rapid as with the lower dose (P &amp;lt; .001) and correlated with an increase in percentage body fat (r = .64; P &amp;lt; .001) and with adrenal size increase over 1 year (r = .32; P = .03). The ratio of bone age to height age was lower in the high-dose group after 3 years of treatment (P = .007).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>The commonly used IGF-I dosage of 120 \u03bcg\/kg twice a day is excessive in comparison to a dose of 80 \u03bcg\/kg twice a day, disproportionately accelerating osseous maturation, probably from the combined effects of obesity and inappropriate adrenal growth, thus likely compromising adult height potential. Moreover, the lower dose decreases direct treatment cost by one-third.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2012-3704","type":"journal-article","created":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T07:25:54Z","timestamp":1358925954000},"page":"839-845","source":"Crossref","is-referenced-by-count":21,"title":["Recommended IGF-I Dosage Causes Greater Fat Accumulation and Osseous Maturation Than Lower Dosage and May Compromise Long-term Growth Effects"],"prefix":"10.1210","volume":"98","author":[{"given":"Jaime","family":"Guevara-Aguirre","sequence":"first","affiliation":[{"name":"Instituto de Endocrinolog\u00eda, Metabolismo y Reproducci\u00f3n (J.G.-A., A.L.R., M.G.-A., J.S., P.P.), 6337 Quito, Ecuador"},{"name":"Division of Pediatric Endocrinology (J.G.-A., A.L.R.), University of Florida College of Medicine, Gainesville, Florida 32608"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlan L.","family":"Rosenbloom","sequence":"additional","affiliation":[{"name":"Instituto de Endocrinolog\u00eda, Metabolismo y Reproducci\u00f3n (J.G.-A., A.L.R., M.G.-A., J.S., P.P.), 6337 Quito, Ecuador"},{"name":"Division of Pediatric Endocrinology (J.G.-A., A.L.R.), University of Florida College of Medicine, Gainesville, Florida 32608"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Guevara-Aguirre","sequence":"additional","affiliation":[{"name":"Instituto de Endocrinolog\u00eda, Metabolismo y Reproducci\u00f3n (J.G.-A., A.L.R., M.G.-A., J.S., P.P.), 6337 Quito, Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannette","family":"Saavedra","sequence":"additional","affiliation":[{"name":"Instituto de Endocrinolog\u00eda, Metabolismo y Reproducci\u00f3n (J.G.-A., A.L.R., M.G.-A., J.S., P.P.), 6337 Quito, Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Procel","sequence":"additional","affiliation":[{"name":"Instituto de Endocrinolog\u00eda, Metabolismo y Reproducci\u00f3n (J.G.-A., A.L.R., M.G.-A., J.S., P.P.), 6337 Quito, Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071618055890500_B1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12325-008-0136-5","article-title":"Mecasermin (recombinant human insulin like growth factor-I)","volume":"26","author":"Rosenbloom","year":"2009","journal-title":"Adv Ther"},{"key":"2020071618055890500_B2","first-page":"629","article-title":"Two year treatment of growth hormone receptor deficiency (GHRD) with recombinant insulin-like growth factor-I in 22 children: comparison of two dosage levels and to GH treated GH deficiency","volume":"82","author":"Guevara-Aguirre","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618055890500_B3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2265.1995.tb02649.x","article-title":"Long-term effects of insulin-like growth factor (IGF)-I treatment of serum IGFs and IGF binding proteins in adolescent patients with growth hormone receptor deficiency","volume":"42","author":"Wilson","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071618055890500_B4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1046\/j.1365-2265.1999.00887.x","article-title":"Growth response to rhIGF-I 80 \u03bcg\/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype","volume":"51","author":"Azcona","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071618055890500_B5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1515\/JPEM.1997.10.4.443","article-title":"Five year treatment with IGF-I of a patient with Laron syndrome in Slovenia (a follow-up report)","volume":"10","author":"Kr\u017ei\u0161nik","year":"1997","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020071618055890500_B6","volume-title":"Increlex [package insert]","year":"2005"},{"key":"2020071618055890500_B7","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1210\/jc.2006-1610","article-title":"GH insensitivity syndrome collaborative group. long-term treatment with recombinant IGF-I in children with severe IGF-I deficiency due to growth hormone insensitivity","volume":"92","author":"Chernausek","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618055890500_B8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/BF03347088","article-title":"Long-term auxological and pubertal outcome of patients with hereditary insulin like growth factor-I deficiency (Laron and growth hormone-gene deletion syndrome) treated with recombinant human insulin like growth factor-I","volume":"34","author":"Messina","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"2020071618055890500_B9","first-page":"1393","article-title":"A randomized double-blind, placebo-controlled trial of safety and efficacy of recombinant insulin-like growth factor-I in children with growth hormone receptor deficiency","volume":"80","author":"Guevara-Aguirre","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618055890500_B10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1651-2227.1994.tb13306.x","article-title":"Body changes in adolescent patients with growth hormone receptor deficiency receiving recombinant human insulin-like growth factor I and luteinizing hormone-releasing hormone analog: preliminary results","volume":"399","author":"Martinez","year":"1994","journal-title":"Acta Paediatr Suppl"},{"key":"2020071618055890500_B11","volume-title":"Radiographic Atlas of Skeletal Development of the Hand and Wrist","author":"Greulich","year":"1959","edition":"2nd ed"},{"key":"2020071618055890500_B12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-3-642-11183-9_42","article-title":"IGF-I treatment of patients with Laron syndrome","volume-title":"Laron Syndrome\u2014From Man to Mouse","author":"Laron","year":"2011"},{"key":"2020071618055890500_B13","first-page":"128","article-title":"Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes","volume":"51","author":"Ranke","year":"1999","journal-title":"Horm Res"},{"key":"2020071618055890500_B14","first-page":"273","article-title":"Hormonal and metabolic effects and pharmacokinetics of recombinant human insulin-like growth factor-I in growth hormone receptor deficiency\/Laron syndrome","volume":"77","author":"Vaccarello","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618055890500_B15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00431-009-1004-2","article-title":"Long-term treatment with recombinant insulin like growth factor 1 (IGF-1) in a child with IGF-I gene mutation","volume":"169","author":"Concolino","year":"2010","journal-title":"Eur J Pediatr"},{"key":"2020071618055890500_B16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/1043-2760(94)P3205-L","article-title":"Growth in growth hormone insensitivity","volume":"5","author":"Rosenbloom","year":"1994","journal-title":"Trends Endocrinol Metab"},{"key":"2020071618055890500_B17","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1056\/NEJM199410203311604","article-title":"Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man","volume":"331","author":"Smith","year":"1994","journal-title":"N Engl J Med"},{"key":"2020071618055890500_B18","first-page":"3689","article-title":"Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens","volume":"80","author":"Morishima","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618055890500_B19","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/oby.2010.305","article-title":"Bone age advancement in prepubertal children with obesity and premature adrenarche: possible potentiating factors","volume":"19","author":"Sopher","year":"2011","journal-title":"Obesity"},{"key":"2020071618055890500_B20","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1210\/jcem.83.10.5204","article-title":"Effect of obesity on estradiol level, and its relationship to leptin, bone maturation, and bone mineral density in children","volume":"83","author":"Klein","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071618055890500_B21","doi-asserted-by":"crossref","first-page":"70ra13","DOI":"10.1126\/scitranslmed.3001845","article-title":"Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer and diabetes in humans","volume":"3","author":"Guevara-Aguirre","year":"2011","journal-title":"Sci Transl Med"},{"key":"2020071618055890500_B22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ghir.2005.12.001","article-title":"Long-term IGF-I treatment of children with Laron syndrome increases adiposity","volume":"16","author":"Laron","year":"2006","journal-title":"Growth Horm IGF Res"},{"key":"2020071618055890500_B23","unstructured":"Tercica says its Increlex provides significant price advantage. The Pharmaletter Web site. http:\/\/www.thepharmaletter.com\/file\/30151\/tercica-says-its-increlex-provides-significant-price-advantage.html. Accessed July 25, 2012."},{"key":"2020071618055890500_B24","first-page":"703","article-title":"Treatment of dwarfism with recombinant human insulin like growth factor-1","volume":"106","author":"Ranke","year":"2009","journal-title":"Dtsch Arztebl Int"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/2\/839\/13653197\/jcem0839.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/2\/839\/13653197\/jcem0839.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:45:45Z","timestamp":1594957545000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/98\/2\/839\/2833400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,1]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2012-3704","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,1]]}}}